<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01636505</url>
  </required_header>
  <id_info>
    <org_study_id>ECK011170</org_study_id>
    <nct_id>NCT01636505</nct_id>
  </id_info>
  <brief_title>The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to performed a randomized controlled trial to evaluate the rate of
      genetic and chromosomal abnormalities in embryos obtained from GnRH-agonist long and
      GnRH-antagonist ovarian stimulation protocols.

      Patients will be prospectively randomized in two groups: the first undergoing controlled
      ovarian stimulation in GnRH-agonist long protocol and the second following GnRH-antagonist
      ovarian stimulation regimen.

      The end-points of the study include the number of genetically and chromosomally abnormal
      embryos, the pregnancy, the implantation and the healthy baby birth rate.

      The patients included in PGS program were selected on the base of advanced maternal age,
      repeated pregnancy lost and implantation failure whereas the patients who were know to carry
      sex-linked or monogenic disorders were considered for PGD strategy.

      The uterine abnormalities, endometriosis and endocrinal diseases were considered to be the
      exclusion factors.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of embryos obtained from GnRH-agonist long and GnRH-antagonist ovarian stimulation protocol</measure>
    <time_frame>one year</time_frame>
    <description>difference in embryos' genetic and chromosomal quality using two different ovarian stimulation protocol</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Embryo's Genetic and Chromosomal Quality</condition>
  <arm_group>
    <arm_group_label>short protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>gnrh agonist versus gnrh antagonist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>long protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ghrh antagonist (cetrotide/orgalutran)</intervention_name>
    <description>cetrotide/orgalutran 0.25 mg</description>
    <arm_group_label>short protocol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gnrh agonist (suprefact)</intervention_name>
    <description>suprefact 5.5 ml</description>
    <arm_group_label>long protocol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients carrier genetic disease

          -  advanced maternal Age

          -  repeated IVF failure

          -  recurrent pregnancy loss

        Exclusion Criteria:

          -  uterine abnormalities

          -  endometriosis

          -  endocrinal diseases
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>46 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>European Hospital</name>
      <address>
        <city>Rome</city>
        <zip>00148</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ermanno Greco, MD</last_name>
      <phone>06-65975643</phone>
      <email>ergreco@virgilio.it</email>
    </contact>
    <investigator>
      <last_name>Ermanno greco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2012</study_first_submitted>
  <study_first_submitted_qc>July 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2012</study_first_posted>
  <last_update_submitted>July 9, 2012</last_update_submitted>
  <last_update_submitted_qc>July 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Cetrorelix</mesh_term>
    <mesh_term>Buserelin</mesh_term>
    <mesh_term>Ganirelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

